Medic Shoes
Shoes for Circulation Improvement
Company Overview
Snapshot
Founded in January 2011, Medic Shoes operates with 1–10 employees. The company's product has received both FDA and CE approval and is registered with the American FDA.
Business overview
Medic Shoes offers a natural solution designed to enhance peripheral circulation and increase blood flow. The company's core product, Medic Shoes, utilizes reflexology principles with raised areas and a vibration mechanism to apply pressure to specific foot points. This treatment aims to provide relief from foot pain, tingling, and numbness by increasing blood flow. Medic Shoes operates within the Health Tech & Life Sciences sector, specifically focusing on medical devices and medical treatment & therapeutics, serving patients and consumers in geomarkets including the United States, China, and Japan.
Strategic signal
In November 2013, Medic Shoes announced its participation in the MEDICA FAIR, a significant event for medical technology. This presentation signaled the company's intent to gain international exposure and validate its product within the global medical device market, indicating early commercialization efforts and a push for broader industry recognition.
Log in to access full profile ›Company Intelligence Q&A
- What is the primary function of Medic Shoes' product?
- Medic Shoes offers a natural solution for enhancing peripheral circulation and increasing blood flow, designed to alleviate foot pain, tingling, and numbness.
- When was Medic Shoes founded?
- Medic Shoes was founded in January 2011.
- Has Medic Shoes received regulatory approvals for its product?
- Yes, the Medic Shoes product has both FDA and CE approval and is registered with the American FDA.
- What was a key early commercialization event for Medic Shoes?
- In November 2013, Medic Shoes was presented at the MEDICA FAIR, a significant medical technology exhibition.
- What is the current operational status of Medic Shoes?
- Medic Shoes is currently non-active, having ceased to operate in March 2025.